GGrantIndex
← Leaderboards

Alessandra D'azzo

St. Jude Children'S Research Hospital

$11,375,286
Attributed
$14,417,570
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY200521
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$14,417,570 · 10

By mechanism

R01$8,512,344 · 6
R44$3,929,648 · 2
RF1$1,750,578 · 1
R43$225,000 · 1

Top collaborators

Others in their field

Top investigators on “Base

Research focus

BaseLeadBiochemicalIn VivoAffectMouse ModelChildhoodLysosomal Storage DiseasesMediatingNerve DegenerationProteinsMolecularPathogenesisComplexHomeostasisDesignHuman DiseaseGeneticLysosomesBrainEnzymesPhenotypePropertyPlay

Grant awards (34)

Dissecting the role of NEU1-dependent de-sialylation in neurodegeneration and neuroinflammation$1,750,578
RF1 · FY2021 · NS · contact PI
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,071,897
R44 · FY2018 · NS
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,366,586
R44 · FY2017 · NS
Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice$113,683
R01 · FY2017 · GM · contact PI
Gene Transfer for Galactosialidosis - Resub$711,009
R01 · FY2016 · DK · contact PI
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$659,425
R44 · FY2016 · NS
Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice$332,500
R01 · FY2016 · GM · contact PI
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease$831,740
R44 · FY2015 · NS
Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice$332,500
R01 · FY2015 · GM · contact PI
Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice$332,500
R01 · FY2014 · GM · contact PI
Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease$225,000
R43 · FY2014 · NS
Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice$332,500
R01 · FY2013 · GM · contact PI
GM1 as apoptotic signal in neurodegenerative GM1-gangliosidosis$420,000
R01 · FY2010 · DK · contact PI
GM1 at the ER-mitochondrion microdomains regulates Ca2+ signaling and apoptosis$232,912
R01 · FY2010 · NS · contact PI
GM1 as apoptotic signal in neurodegenerative GM1-gangliosidosis$420,000
R01 · FY2009 · DK · contact PI
Functional/Structural Studies of Mammalian Neuraminidase$383,351
R01 · FY2009 · GM · contact PI
GM1 at the ER-mitochondrion microdomains regulates Ca2+ signaling and apoptosis$229,137
R01 · FY2009 · NS · contact PI
Functional/Structural Studies of Mammalian Neuraminidase$108,624
R01 · FY2009 · GM · contact PI
Functional/Structural Studies of Mammalian Neuraminidase$381,640
R01 · FY2008 · GM · contact PI
Specificity and Activity of Ozz-E3 During Myogenesis$216,694
R01 · FY2008 · AR · contact PI
Functional/Structural Studies of Mammalian Neuraminidase$374,794
R01 · FY2007 · GM · contact PI
Specificity and Activity of Ozz-E3 During Myogenesis$221,950
R01 · FY2007 · AR · contact PI
Functional/Structural Studies of Mammalian Neuraminidase$379,525
R01 · FY2006 · GM · contact PI
Specificity and Activity of Ozz-E3 During Myogenesis$229,009
R01 · FY2006 · AR · contact PI
Specificity and Activity of Ozz-E3 During Myogenesis$236,900
R01 · FY2005 · AR
Specificity and Activity of Ozz-E3 During Myogenesis$259,780
R01 · FY2004 · AR
Cell-Specific Gene Therapy for Lysosomal Diseases$234,375
R01 · FY2004 · DK
FUNCTIONAL/STRUCTURAL STUDIES OF MAMMALIAN NEURAMINIDASE$331,007
R01 · FY2003 · GM
Cell-Specific Gene Therapy for Lysosomal Diseases$234,375
R01 · FY2003 · DK
FUNCTIONAL/STRUCTURAL STUDIES OF MAMMALIAN NEURAMINIDASE$321,452
R01 · FY2002 · GM
Cell-Specific Gene Therapy for Lysosomal Diseases$318,750
R01 · FY2002 · DK
FUNCTIONAL/STRUCTURAL STUDIES OF MAMMALIAN NEURAMINIDASE$310,443
R01 · FY2001 · GM
FUNCTIONAL/STRUCTURAL STUDIES OF MAMMALIAN NEURAMINIDASE$301,151
R01 · FY2000 · GM
CELL SPECIFIC GENE THERAPY FOR LYSOSOMAL DISEASES$211,783
R01 · FY2000 · DK